Prostate CancerPPPNCT07741929
Patient and Provider Perspectives on Genetic Risk Profiling
An observational study of Prostate Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice. Read more about this study
- Who is it for?
- Ages 18 to 100 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Qualitative interview
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 May 2026to 31 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients who have undergone and received a genetic risk profiling result for prostate cancer and healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Who may be able to join
- Individuals assigned male at birth who are aged 18 and over and who have capacity to consent
- Patients who have undergone genetic risk profiling for prostate cancer and have received their results
- Individuals from diverse backgrounds (age, ethnicity, risk status, etc)
- Healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Who cannot join
- Individuals who lack capacity to consent
- Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
The Royal Marsden Hospital (Sutton and Chelsea)
London, SM2 5PT
Tarryn Shaw, MSc Genetic Counselling, 0208 722 4483, tarryn.shaw@rmh.nhs.uk
Elizabeth Bancroft, RN PhD, 0208 722 4483, elizabeth.bancroft@rmh.nhs.uk
About this study
Official title: Exploring the Patient and Provider Perspectives on the Utility of Genetic Risk Profiling for Prostate Cancer in Routine Clinical Practice
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.
Read the detailed description
Prostate cancer is the most prevalent cancer in men in the UK, however there are currently no formalised prostate cancer screening and risk management guidelines. Prostate cancer has a large heritable/genetic component and the combination of genetic alterations that a person inherits has a large influence on their risk. Genetic risk profiling can provide information on whether a person has a higher, average or lower genetic risk to develop prostate cancer. This can help to guide screening and management advice, with people at higher risk benefitting from increased surveillance and interventions, while sparing those at lower risk from unnecessary interventions. It can also provide guidance on potential treatments, prevention and reproductive risks and options. This can tailor and personalise healthcare for patients based on their risk, while also providing economic benefits to the healthcare system. Despite the benefits of genetic risk profiling, there are current concerns pertaining to the readiness for it's implementation into routine clinical practice given the lack of current risk management guidelines and uncertainty pertaining to actionability of results. Further research is essential to inform clinical practice.
This study will explore the perspectives of all stakeholders involved in the testing process, namely patients and healthcare providers who respectively receive and deliver genetic risk profiling results, to explore their viewpoints on the utility of genetic risk profiling in routine clinical practice. The research aims to explore current benefits, limitations, concerns and needs pertaining to genetic risk profiling which may contribute towards future research and clinical practice. Patients and providers who have received or delivered these results will be invited to participate in a once-off interview either at the Royal Marsden Hospital in Chelsea or Sutton or via video/telephone consultation. The research will be funded by the Royal Marsden Cancer Charity over 2 years.
- Conditions
- Prostate Cancer
- Being tested
- Qualitative interview
- Keywords
- Patients, Providers, Genetic Risk Profiling, Prostate Cancer, Clinical Utility, Perspectives
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Qualitative interviewOther
Interview of participants to gain perspectives and experiences
| Study group | Role | What they receive |
|---|---|---|
| Patient participants | Diverse cohort of patients who have undergone genetic risk profiling and have received their results Receives: Other: Qualitative interview | |
| Provider participants | Healthcare providers who have delivered genetic risk profiling results to patients Receives: Other: Qualitative interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach.
The study findings will provide data pertaining to the current experiences, perspectives, benefits, limitations and challenges patients and providers encounter when receiving and delivering genetic risk profiling results. The findings can help to highlight areas of concern which need to be addressed, improved and/or implemented prior to clinical implementation of genetic risk profiling into routine clinical care. The findings can also identify the educational, clinical and/or support needs and may also highlight aspects of clinical care which need to be improved or established (e.g. screening guidelines, resources, upskilled workforce) prior to the integration of genetic risk profiling into routine clinical practice. This will ensure that genetic risk profiling is relevant and feasible in terms of improving the clinical care and health seeking behaviours of patients.
Measured: January 2026 to August 2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start1 May 2026
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Royal Marsden NHS Foundation TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Institute of Cancer Research, United Kingdom
- Responsible party
- Sponsor
- Investigators
- Elizabeth Bancroft, RN PhD, Principal investigator, The Royal Marsden NHS Foundation Trust / The Institute of Cancer Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07741929
- Sponsor's protocol ID
- CCR6285
- Acronym
- PPP
- Status last verified
- Jul 2026
- First submitted
- 14 Apr 2026
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Only if participants consent to future research / sharing of research data
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Patient and Provider Perspectives on the Utility of Genetic Risk Profiling for Prostate Cancer in Routine Clinical Practice
- ClinicalTrials.gov ID
- NCT07741929
- Acronym / sponsor ID
- PPP / CCR6285
- Conditions
- Prostate Cancer
- Keywords
- Patients, Providers, Genetic Risk Profiling, Prostate Cancer, Clinical Utility, Perspectives
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Royal Marsden NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Institute of Cancer Research, United Kingdom
- Study start
- 1 May 2026 (actual)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.
Detailed description
Prostate cancer is the most prevalent cancer in men in the UK, however there are currently no formalised prostate cancer screening and risk management guidelines. Prostate cancer has a large heritable/genetic component and the combination of genetic alterations that a person inherits has a large influence on their risk. Genetic risk profiling can provide information on whether a person has a higher, average or lower genetic risk to develop prostate cancer. This can help to guide screening and management advice, with people at higher risk benefitting from increased surveillance and interventions, while sparing those at lower risk from unnecessary interventions. It can also provide guidance on potential treatments, prevention and reproductive risks and options. This can tailor and personalise healthcare for patients based on their risk, while also providing economic benefits to the healthcare system. Despite the benefits of genetic risk profiling, there are current concerns pertaining to the readiness for it's implementation into routine clinical practice given the lack of current risk management guidelines and uncertainty pertaining to actionability of results. Further research is essential to inform clinical practice.
This study will explore the perspectives of all stakeholders involved in the testing process, namely patients and healthcare providers who respectively receive and deliver genetic risk profiling results, to explore their viewpoints on the utility of genetic risk profiling in routine clinical practice. The research aims to explore current benefits, limitations, concerns and needs pertaining to genetic risk profiling which may contribute towards future research and clinical practice. Patients and providers who have received or delivered these results will be invited to participate in a once-off interview either at the Royal Marsden Hospital in Chelsea or Sutton or via video/telephone consultation. The research will be funded by the Royal Marsden Cancer Charity over 2 years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patient participants | – | Other: Qualitative interviewDiverse cohort of patients who have undergone genetic risk profiling and have received their results |
| Provider participants | – | Other: Qualitative interviewHealthcare providers who have delivered genetic risk profiling results to patients |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have undergone and received a genetic risk profiling result for prostate cancer and healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Key inclusion criteria (4 listed)
- Individuals assigned male at birth who are aged 18 and over and who have capacity to consent
- Patients who have undergone genetic risk profiling for prostate cancer and have received their results
- Individuals from diverse backgrounds (age, ethnicity, risk status, etc)
- Healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Key exclusion criteria (2 listed)
- Individuals who lack capacity to consent
- Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Qualitative interviewInterview of participants to gain perspectives and experiences | Other | Patient participants, Provider participants |
Primary outcome
Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach.
Time frame: January 2026 to August 2027
The study findings will provide data pertaining to the current experiences, perspectives, benefits, limitations and challenges patients and providers encounter when receiving and delivering genetic risk profiling results. The findings can help to highlight areas of concern which need to be addressed, improved and/or implemented prior to clinical implementation of genetic risk profiling into routine clinical care. The findings can also identify the educational, clinical and/or support needs and may also highlight aspects of clinical care which need to be improved or established (e.g. screening guidelines, resources, upskilled workforce) prior to the integration of genetic risk profiling into routine clinical practice. This will ensure that genetic risk profiling is relevant and feasible in terms of improving the clinical care and health seeking behaviours of patients.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
- Individual participant dataSharing planned: Undecided. Only if participants consent to future research / sharing of research data
Related trials for Prostate Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Not yet recruitingPhase 3
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Metastatic Prostate Cancer
RecruitingPhase 2
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Prostate Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Elizabeth Bancroft, RN PhD principal investigator
The Royal Marsden NHS Foundation Trust / The Institute of Cancer Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tarryn Shaw, MSc (020 8661 3375, tarryn.shaw@rmh.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach. (time frame: January 2026 to August 2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.